Abstract
The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Current Molecular Medicine
Title: The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Volume: 8 Issue: 2
Author(s): Kerstin Reimers, Claudia Y.U. Choi, Vesna Bucan and Peter M. Vogt
Affiliation:
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Abstract: The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Export Options
About this article
Cite this article as:
Reimers Kerstin, Choi Y.U. Claudia, Bucan Vesna and Vogt M. Peter, The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis, Current Molecular Medicine 2008; 8 (2) . https://dx.doi.org/10.2174/156652408783769562
DOI https://dx.doi.org/10.2174/156652408783769562 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders
Current Medicinal Chemistry Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Pharmacogenomics of COPD
Current Pharmacogenomics Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
Current Radiopharmaceuticals Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design A Closer Look at α-Secretase
Current Alzheimer Research Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine